220 related articles for article (PubMed ID: 37919903)
1. A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy.
Lee IK; Sharma N; Noguera-Ortega E; Liousia M; Baroja ML; Etersque JM; Pham J; Sarkar S; Carreno BM; Linette GP; Puré E; Albelda SM; Sellmyer MA
Mol Ther; 2023 Dec; 31(12):3564-3578. PubMed ID: 37919903
[TBL] [Abstract][Full Text] [Related]
2. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene.
Sellmyer MA; Richman SA; Lohith K; Hou C; Weng CC; Mach RH; O'Connor RS; Milone MC; Farwell MD
Mol Ther; 2020 Jan; 28(1):42-51. PubMed ID: 31668558
[TBL] [Abstract][Full Text] [Related]
3. Regulation of eDHFR-tagged proteins with trimethoprim PROTACs.
Etersque JM; Lee IK; Sharma N; Xu K; Ruff A; Northrup JD; Sarkar S; Nguyen T; Lauman R; Burslem GM; Sellmyer MA
Nat Commun; 2023 Nov; 14(1):7071. PubMed ID: 37923771
[TBL] [Abstract][Full Text] [Related]
4. Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand.
Sun J; Zhang W; Zhao Y; Liu J; Wang F; Han Y; Jiang M; Li S; Tang D
Cytotherapy; 2021 Dec; 23(12):1085-1096. PubMed ID: 34593327
[TBL] [Abstract][Full Text] [Related]
5. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.
Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP
Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography.
Sakemura R; Cox MJ; Bansal A; Roman CM; Hefazi M; Vernon CJ; Glynn DL; Pandey MK; DeGrado TR; Siegler EL; Kenderian SS
J Vis Exp; 2022 Feb; (180):. PubMed ID: 35253798
[TBL] [Abstract][Full Text] [Related]
7. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
9. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
10. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
11. A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology.
Lee SM; Kang CH; Choi SU; Kim Y; Hwang JY; Jeong HG; Park CH
ACS Synth Biol; 2020 May; 9(5):987-992. PubMed ID: 32352759
[TBL] [Abstract][Full Text] [Related]
12. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
14. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
15. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.
Zhang E; Xu H
J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484
[TBL] [Abstract][Full Text] [Related]
16. Advances in modular control of CAR-T therapy with adapter-mediated CARs.
McCue AC; Yao Z; Kuhlman B
Adv Drug Deliv Rev; 2022 Aug; 187():114358. PubMed ID: 35618140
[TBL] [Abstract][Full Text] [Related]
17. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
18. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol.
Yang L; Yin J; Wu J; Qiao L; Zhao EM; Cai F; Ye H
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34404729
[TBL] [Abstract][Full Text] [Related]
19. An in vivo covalent TMP-tag based on proximity-induced reactivity.
Gallagher SS; Sable JE; Sheetz MP; Cornish VW
ACS Chem Biol; 2009 Jul; 4(7):547-56. PubMed ID: 19492849
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
